Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial

Amycretin is a novel unimolecular agonist of GLP-1 and amylin receptors developed by Novo Nordisk for the treatment of type 2 diabetes and obesity2 1.

In the Phase 2 trial, once-weekly subcutaneous amycretin led to a statistically significant weight loss of up to 14.5% at 36 weeks; oral administration achieved up to 10.1% weight loss2 4 6.

HbA1c reductions (a measure of blood sugar control) reached up to -1.8% from a baseline of 7.8%, with up to 89.1% of participants achieving HbA1c below 7%2 6 8.

The improvements in both weight and HbA1c were statistically significant compared to placebo recipients, who saw much smaller effects (-2.6% weight loss subcutaneous, -2.5% oral; -0.2% and -0.4% HbA1c respectively)2 6 8.

No plateau in weight loss was observed at 36 weeks for higher doses, suggesting continued potential benefit2.

The most common side effects were gastrointestinal and mostly mild to moderate, with an overall safety profile similar to other incretin and amylin-based therapies2 5.

Roughly 40% of patients were also on SGLT2 inhibitors as background therapy1.

Novo Nordisk plans to start an extensive phase 3 development program for amycretin in type 2 diabetes and potentially other indications in 20261 2.